acib - THE AUSTRIAN CENTRE OF INDUSTRIAL BIOTECHNOLOGY

THE AUSTRIAN CENTRE
OF INDUSTRIAL BIOTECHNOLOGY

acib is an international competence centre, developing new, environmentally friendly, economically and technically advanced processes for the biotechnological, pharmaceutical and chemical industry – all of them modelled on nature. acib is bridging the gap between academic research and producing industry. The big advantage for acib partner organisations is the possibility to translate scientific results into concrete processes and product by using scientific know-how, academic infrastructure or industrial networks. Our platform offers tailor-made solutions for our stakeholders from Academia, Industry and Investors.

LATEST BLOG ARTICLES

Targeting cancer

The complex tumour structure makes the treatment of breast cancer a medical challenge. A promising, novel selenium-based breast cancer nanoparticle therapy, which is topic of the EU-project Neosetac, could change that: It has proved to boost the active agent delivery and assure it’s active only in the target tissue while also bringing the suggestion of reduced side effects. The project findings are expected to increase the efficiency of future chemotherapies and prevent recurrence of the cancer after complete remission.

Read more
Myths and facts about crowdinvesting

In our previous article Insights into crowdfunding the concept of crowdfunding was explained while the following article focuses on investment. Crowdinvesting is not a miracle. However, there are a few myths due to misinformation about some basic principles and due to still changing legal provisions of this new financial instrument. Some of these myths are related to the expectations about the parties involved. The following facts are supposed to dismantle the myths of crowdinvesting.

Read more
Den Enzos auf der Spur

Auf das Abenteuer Forschung haben sich im Rahmen des Projektes „Enzyme im Alltag“ neun Schulklassen aus Volksschulen, NMS und Gymnasien eingelassen. Gemeinsam mit Wissenschaftlerinnen und Wissenschaftlern vom acib und der TU Graz und den Firmenpartnern Bisy, Qualizyme und QPS erkundeten die Kinder und ihre Lehrkräfte innerhalb von 2 Jahren die enorme Vielfalt enzymatischer Abläufe und entdeckten sie im täglichen Leben.

Read more
How sugar beets sweeten our life

Sugar is not only a widely used food ingredient but can also be used as possible starting point for high-added-value products. The European research consortium of CARBAFIN explores different ways to make use of sugar beet biomass: the sugar components glucose and fructose are starting points for the production of important ingredients for not only food/feed but also cosmetics. Besides, fructose can be further converted to a platform chemical, which is applied to the production of bioplastics, biofuels or biopolymers, as well as resins. In other words, CARBAFIN people sweeten our lives!

Read more
P450 CYPs and Capsaicin – a hot new way of simulating drug-metabolism outside the human body

Have you ever wondered, why it often takes many years until a new drug is available at your local pharmacy? One of the reasons is that the pharmaceutical industry wants to make sure that the drug is not only effective but also doesn’t produce toxic breakdown products that lead to undesireable side effects. Therefore, many time-consuming and not seldomly expensive tests are required to know precisely, which possible metabolic by-products could emerge. In a next step, the industry is producing such derivates to test them thoroughly for their side-effects, ensuring one goal: the patients health and wellbeing.

Read more
Biosensors for blood grouping

Biosensors may soon facilitate the analysis of a patient’s entire red blood cell antigen repertoire. In the form of diagnostic test strips, they could make the analysis swift and location-independent. This could have enormous potential not only in medical diagnosis, but also for environmental analysis if extended to other analytes.

Read more
Insights into crowdfunding

Crowdfunding became known around 2005/06 in the creative industries. To cope with illegal downloads in the music industries, money was raised before publishing. However, the concept of crowdfunding is much older. In 1885 the Statute of Liberty would not have been completed without a newspaper-led campaign (by Joseph Pulitzer of the New York World) that attracted 160,000 donors.

Read more
Presentation Design: a worthwhile investment of time for scientists?

Conference season has already started and scientists begin to mingle and present their latest achievements. The lecture rooms are flooded with an overwhelming number of data sets and graphs and crowded PowerPoint slides are the norm. What makes the difference between a good and an excellent presentation is not only the content and the speaker, but also the design of the presentation itself. But, do scientist really have time for that?

Read more
Introducing microbiome researchers

Microorganisms play a crucial role for the health and well-being of higher organisms. Host-specific microbial communities of varying complexity form the so-called microbiota. It can consist of several thousand microbial species and includes bacteria, archaea and fungi. These microorganisms exchange a plethora of metabolites with their hosts and can modulate their functioning. Such interactions equally affect humans, animals and plants. This provides us with novel strategies to counteract various diseases and increase the resistance of higher organisms towards abiotic and biotic stresses by modulating the microbiota.

Read more
Do not fear the shear!

Since the early days of bioprocess engineering shear associated protein aggregation was believed to be a real thread for proteins causing a decrease in production yield accompanied by higher costs. Although some research indicated that moderate shear rates do not aggregate proteins, the scientific consensus today is still not aligned. Recent results suggested that elongational forces, very similar to shear, can unfold proteins. Hence, there is a strong demand for a technical solution to describe extraordinary high shear rates and investigate their impact on protein aggregation, to answer this unsolved mystery in bioprocess engineering.

Read more

COMPANY PROFILE AND OWNERS

acib is an industrially oriented private limited company with a non-profit orientation. It is publicly owned by:

K2 RESEARCH CENTRE

acib is funded as a K2 research centre in the framework of FFG COMET funding (Competence Centres for Excellent Technologies) by BMVIT, BMWF, and the provinces of Styria, Vienna, Lower Austria and Tyrol. The COMET programme is processed via FFG. 18 scientific partners are involved in the implementation of the acib COMET programme, which is co-funded by 53 industrial partners.

More about COMET